Infrastructure improvements
Ended Awarded Last action
- Contract number
- 75N91021F00018
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,082,230
Award facts
- Opportunity
-
- NCIOSFM210120 Solicitation number
- Contract value 100% obligated
- $4,082,230.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Terminate for Convenience | -$527,581 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $4,609,811 |
Show all 13
About this award
The National Cancer Institute awarded a delivery order contract to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., for infrastructure improvements at the Frederick, Maryland facility. The contract, valued at approximately $4.1 million with a Cost Plus Fixed Fee pricing structure, was awarded on September 27, 2021, and is scheduled for completion by September 24, 2026. This delivery order is part of a broader federal contracting vehicle and carries no set-aside designation, reflecting the contractor's competitive standing as a large, established government contractor. The work aligns with the National Cancer Institute's operational support needs at its Frederick National Laboratory for Cancer Research facility.
Leidos Biomedical Research Inc. serves as a Federally Funded Research and Development Center contractor supporting the National Cancer Institute and broader National Institutes of Health missions. The company specializes in biomedical research and facilities support services, including medical research, clinical trials, facility management, and advanced technological solutions. The infrastructure improvement initiative referenced in the award description indicates the contractor will support the Department of Government Efficiency cost efficiency initiative as of March 19, 2025, suggesting the delivery order may encompass facility optimization and operational enhancements consistent with federal cost management directives. This contract represents part of Leidos' significant role in supporting critical federal scientific research infrastructure and operations.
Quick answers
Who was awarded contract 75N91021F00018?
75N91021F00018 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 27, 2021.
How much is contract 75N91021F00018 worth?
The government has obligated $4,082,230 on 75N91021F00018.
Is contract 75N91021F00018 an order under another contract?
Yes. 75N91021F00018 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91021F00018 competed?
The extent of competition for 75N91021F00018 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award